Loading
NASDAQHealthcareMedical - Devices
Latest quote
$18.40
+$0.50 · +2.79%
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Latest quote
$18.40
+$0.50 · +2.79%
After-hours
$18.69
+$0.29 · +1.58%
Oct 9, 7:58 PM ET
Regular session · ET · Market data may be delayed.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Day range
Current $18.40
52-week range
Current $18.40
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
96
Deep Value
Sentiment
69
Bullish
Risk
64
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Day range
Current $18.40
52-week range
Current $18.40
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 308.05M USD | 224.5M USD | 136.19M USD | 75.01M USD | 34.47M USD |
| Cost of goods sold | 111.83M USD | 87.4M USD | 65.14M USD | 37.93M USD | 18.61M USD |
| Gross profit | 196.23M USD | 137.1M USD | 71.05M USD | 37.09M USD | 15.87M USD |
| Research and development | 71.28M USD | 62.3M USD | 48.45M USD | 28.98M USD | 18.99M USD |
| Selling, general, and administrative | 228.81M USD | 171.42M USD | 131.77M USD | 88.83M USD | 51.04M USD |
| Operating expenses | 300.09M USD | 233.71M USD | 180.22M USD | 117.81M USD | 70.03M USD |
| Interest income | 12.22M USD | 10.9M USD | 7.55M USD | 2.5M USD | 76K USD |
| Interest expense | 3.59M USD | 4.18M USD | 4M USD | 5.18M USD | 5.81M USD |
| Depreciation and amortization | 6.39M USD | 5.23M USD | 3.81M USD | 2.84M USD | 3.32M USD |
| Operating income | −103.86M USD | −96.61M USD | −109.17M USD | −80.72M USD | −54.16M USD |
| Net income | −95.57M USD | −91.41M USD | −105.9M USD | −87.15M USD | −59.85M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$23.00
25.00% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI36.21M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM26.36M0.03%77.7B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB26.35M0.01%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK15.1M0.03%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF14.01M0.01%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO9.37M0.07%14.04B USD0.24%$356.78+0.94%
Global X - Robotics & Artificial Intelligence ETFBOTZ8.6M0.26%3.31B USD0.68%$35.48+1.87%
Vanguard Russell 2000 ETFVTWO6.84M0.04%18B USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOGlobal X - Robotics & Artificial Intelligence ETFBOTZVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
